Assetmark, Inc Biogen Inc. Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Biogen Inc. stock. As of the latest transaction made, Assetmark, Inc holds 29 shares of BIIB stock, worth $5,039. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 477 93.92%

Holding current value

$5,039

Previous $110,000 95.45%

% of portfolio

0.0%

Previous 0.0%

36 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$189.07 - $236.8 $84,703 - $106,086	-448 Reduced 93.92%	29 $5,000
Q2 2024 Aug 13, 2024	SELL	$190.52 - $236.72 $861,150 - $1.07 Million	-4,520 Reduced 90.45%	477 $110,000
Q1 2024 May 06, 2024	SELL	$212.02 - $267.71 $8,056 - $10,172	-38 Reduced 0.75%	4,997 $1.08 Million
Q4 2023 Feb 09, 2024	BUY	$222.59 - $267.94 $35,836 - $43,138	161 Added 3.3%	5,035 $1.3 Million
Q3 2023 Oct 27, 2023	BUY	$253.3 - $285.89 $104,106 - $117,500	411 Added 9.21%	4,874 $1.25 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $561,510 - $648,842	2,040 Added 84.19%	4,463 $1.27 Million
Q1 2023 May 05, 2023	BUY	$256.56 - $292.34 $94,157 - $107,288	367 Added 17.85%	2,423 $673,000
Q4 2022 Feb 10, 2023	BUY	$252.44 - $306.72 $133,288 - $161,948	528 Added 34.55%	2,056 $569,000
Q3 2022 Nov 01, 2022	BUY	$194.69 - $268.46 $84,495 - $116,511	434 Added 39.67%	1,528 $408,000
Q2 2022 Aug 03, 2022	BUY	$187.54 - $223.02 $116,649 - $138,718	622 Added 131.78%	1,094 $223,000
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $67,625 - $85,204	-349 Reduced 42.51%	472 $99,000
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $19,481 - $25,035	87 Added 11.85%	821 $197,000
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $18 Million - $23.5 Million	-63,735 Reduced 98.86%	734 $208,000
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $39.6 Million - $63.4 Million	-152,762 Reduced 70.32%	64,469 $22.3 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $6.33 Million - $7.42 Million	-26,055 Reduced 10.71%	217,231 $60.8 Million
Q4 2020 Feb 10, 2021	BUY	$236.26 - $355.63 $3.58 Million - $5.39 Million	15,165 Added 6.65%	243,286 $59.6 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $4.63 Million - $5.35 Million	17,504 Added 8.31%	228,121 $64.7 Million
Q2 2020 Aug 11, 2020	BUY	$258.66 - $342.55 $54.3 Million - $71.9 Million	209,925 Added 30335.98%	210,617 $55.7 Million
Q1 2020 May 12, 2020	BUY	$268.85 - $341.04 $115,605 - $146,647	430 Added 164.12%	692 $219,000
Q4 2019 Feb 11, 2020	SELL	$220.06 - $304.07 $21,345 - $29,494	-97 Reduced 27.02%	262 $78,000
Q3 2019 Nov 13, 2019	BUY	$217.44 - $243.88 $9,784 - $10,974	45 Added 14.33%	359 $84,000
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $16,227 - $17,887	-74 Reduced 19.07%	314 $73,000
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $12,352 - $19,320	-57 Reduced 12.81%	388 $92,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $22,280 - $28,220	80 Added 21.92%	445 $134,000
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $17,904 - $23,413	-61 Reduced 14.32%	365 $129,000
Q2 2018 Aug 01, 2018	BUY	$257.52 - $306.91 $2,832 - $3,376	11 Added 2.65%	426 $124,000
Q1 2018 May 16, 2018	SELL	$260.13 - $367.91 $2.06 Million - $2.91 Million	-7,922 Reduced 95.02%	415 $114,000
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $2.45 Million - $2.74 Million	7,948 Added 2043.19%	8,337 $2.66 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $17,712 - $20,770	63 Added 19.33%	389 $122,000
Q2 2017 Aug 15, 2017	SELL	N/A	-1 Reduced 0.31%	326 $88,000
Q1 2017 Sep 15, 2017	BUY	N/A	10 Added 3.15%	327 $89,000
Q4 2016 Sep 15, 2017	SELL	N/A	-98 Reduced 23.61%	317 $90,000
Q3 2016 Sep 15, 2017	BUY	N/A	39 Added 10.37%	415 $130,000
Q2 2016 Sep 15, 2017	SELL	N/A	-2,108 Reduced 84.86%	376 $91,000
Q1 2016 Sep 15, 2017	BUY	N/A	88 Added 3.67%	2,484 $646,000
Q4 2015 Sep 15, 2017	BUY	N/A	2,396	2,396 $734,000

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account